The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2017
Filed:
Mar. 15, 2013
Applicant:
Iheart Japan Corporation, Kyoto-shi, Kyoto, JP;
Inventors:
Jun Yamashita, Kyoto, JP;
Hidetoshi Masumoto, Kyoto, JP;
Assignee:
IHEART JAPAN CORPORATION, Kyoto-shi, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/38 (2006.01); A61L 27/50 (2006.01); C12N 5/071 (2010.01); A61L 27/54 (2006.01); A61K 35/34 (2015.01); A61K 35/44 (2015.01); A61K 35/545 (2015.01); C12N 5/077 (2010.01);
U.S. Cl.
CPC ...
A61L 27/3886 (2013.01); A61K 35/34 (2013.01); A61K 35/44 (2013.01); A61K 35/545 (2013.01); A61L 27/3808 (2013.01); A61L 27/3826 (2013.01); A61L 27/3834 (2013.01); A61L 27/3839 (2013.01); A61L 27/3895 (2013.01); A61L 27/50 (2013.01); A61L 27/54 (2013.01); C12N 5/0602 (2013.01); C12N 5/069 (2013.01); C12N 5/0657 (2013.01); C12N 5/0697 (2013.01); A61L 27/3804 (2013.01); A61L 2300/608 (2013.01); A61L 2300/64 (2013.01); A61L 2430/20 (2013.01); C12N 2500/44 (2013.01); C12N 2501/115 (2013.01); C12N 2501/16 (2013.01); C12N 2501/165 (2013.01); C12N 2501/727 (2013.01); C12N 2502/1329 (2013.01); C12N 2502/28 (2013.01); C12N 2506/45 (2013.01); C12N 2539/10 (2013.01);
Abstract
The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method.